Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21598012 | 0.85 | SMN1; SMN2 (0.37) | SMN1; SMN2ZDHHC7CA1CA2ACHE | |
| SCHEMBL28301320 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2ZDHHC7CA1CA2CA14 | |
| SCHEMBL11287379 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2ZDHHC7CA1CA2CA14 | |
| SCHEMBL30170510 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2ZDHHC7CA1CA2CA14 | |
| SCHEMBL27964961 | 0.78 | ALDH1A1 (0.40) | KMT2AALDH1A1HTTHSD17B10 | |
| SCHEMBL11320047 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2ZDHHC7CA1CA2CA14 | |
| SCHEMBL1241162 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2ZDHHC7CA1CA2ACHE | |
| SCHEMBL3140450 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2ZDHHC7CA1CA2ACHE | |
| SCHEMBL23130631 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2CA1CA2ACHECA14 | |
| SCHEMBL197319 | 0.74 | SMN1; SMN2 (0.40) | SMN1; SMN2ZDHHC7CA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61205234-A | — | — | None | — | — | JP | disclosed |
| EP-4648762-A2 | PPARG MODULATORS | University of Florida Research Foundation, Incorporated (US) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024151519-A2 | PPARG MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-3444254-B1 | HETEROCYCLIC-SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | SHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2019-07-16 | — | — | US | disclosed |
| CN-107286180-B | Miscellaneous generation Pyridopyrimidinone derivatives are as CDK inhibitor and its application | 上海勋和医药科技有限公司 | 2019-07-02 | — | — | CN | disclosed |
| US-20190071453-A1 | Heterocyclic-substituted Pyridinopyrimidinone Derivative as CDK Inhibitor and Use thereof | CHENGDU JINRUI FOUNDATION BIOTECH CO., LTD. (CN) | 2019-03-07 | — | — | US | disclosed |
| EP-3444254-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | Shanghai Xunhe Pharmaceutical Technology Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
| CN-107286180-A | Miscellaneous generation Pyridopyrimidinone derivatives are used as CDK inhibitor and its application | 上海勋和医药科技有限公司 | 2017-10-24 | — | — | CN | disclosed |
| US-20150011528-A1 | PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2015-01-08 | — | — | US | disclosed |
| EP-2758384-A1 | PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Yuhan Corporation (KR) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043001-A1 | PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2013-03-28 | — | — | WO | disclosed |
| CN-100506807-C | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-07-01 | — | — | CN | disclosed |
| CN-101434585-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-05-20 | — | — | CN | disclosed |
| CN-1658871-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2005-08-24 | — | — | CN | disclosed |
| US-5585391-A | Hydroxyl ions as unique therapeutic agents and compounds that modulate these ions, compositions employing these agents, therapeutic methods for using such agents and processes for preparing them | FHJ SCIENTIFIC, INC. (US) | 1996-12-17 | — | — | US | disclosed |
| US-5574050-A | Hydroxyl ions as unique therapeutic agents and processes for preparing them | FHJ SCIENTIFIC, INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5514808-A | Hydroxyl ions as unique therapeutic agents and compounds that modulate these ions | FHJ SCIENTIFIC, INC (US) | 1996-05-07 | — | — | US | disclosed |
| JP-S61205234-A | FLUORINE-CONTAINING HYDROXYCARBOXYLIC ACID ESTER | DAIKIN IND LTD | 1986-09-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071453-A1 | Heterocyclic-substituted Pyridinopyrimidinone Derivative as CDK Inhibitor and Use thereof | CDK4, CDK6, CCNI | SMN1; SMN2 2217/4885ZDHHC7 4063/4885CA1 4698/4885 |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | CDK4, CDK6, CCNI | SMN1; SMN2 2217/4885ZDHHC7 4063/4885CA1 4698/4885 |
| US-20150011528-A1 | PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ILK, PKMYT1, PLAUR | SMN1; SMN2 2126/4885ZDHHC7 3449/4885CA1 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.